tirzepatide and psoriatic arthritis A Study to Investigate Effectiveness of Following Initiation of Ixekizumab in Participants With Active Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) Psoriasis with obesity: adding tirzepatide
Description
Tracking that makes progress obvious Progress can feel slow if you only look at single weigh-ins
Reductions were greater with tirzepatide versus placebo (185.3 kcal [312.7, 57.8]
Firmer erections can also appear longer or fuller, adding to the perception of growth
Denying access to these therapies limits clinicians ability to provide patientcentered care and places employees at increased risk of preventable disease progression
